reMYND
Gerard Griffioen is the Chief Scientific Officer at reMYND NV since September 2002. Prior to that, Gerard worked as a Scientist at K.U.Leuven and as a Post-Doc at the University of Vienna. Gerard holds a PhD in Molecular Biology/Cell Biology from Vrije Universiteit Amsterdam. Gerard specializes in Biochemistry, Cell Biology, Molecular Biology, and Yeast Genetics, with a focus on disease-modifying treatments for Alzheimer's and Parkinson's disease.
reMYND
reMYND drives the development of disease-modifying treatments against protein misfolding disorders.